Setting 
My Cart
Toggle Nav
Close
  • Menu
  • Setting

EZ Cap™ Human P16 mRNA (5-moUTP)

Catalog No.
R1040
Human p16 mRNA with Cap 1 structure, modified by 5-moUTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.
Grouped product items
SizePriceStock Qty
100ug (1mg/mL)
$275.00
In stock
1mg (1mg/mL)
$1,420.00
In stock
5X1mg (1mg/mL)
$5,020.00
In stock
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

P16 gene is an essential gene in the cell cycle, which is directly involved in the regulatory signaling pathway of the cell cycle and plays an important role in the formation and development of tumors. It can inhibit innate or acquired carcinogenic mutations in cells, inhibit the growth and spread of tumor cells by obstructing cell cycle progression and inducing cell aging. The inactivated or missing p16 gene has been linked to the development of a variety of tumors, including melanoma, pancreatic cancer, and cervical cancer.

EZ Cap™ Human P16 mRNA (5-moUTP) is provided at a concentration of ~1mg/mL with Cap1 structure, expressing human P16 protein. There are currently two ways to cap mRNA: One is co-transcription method, by adding Cap analogues into the transcription process. The other is enzymatic Capping. After transcription, Cap0 capping is performed by Vaccinia virus Capping Enzyme (VCE), GTP and S-adenosylmethionine (SAM). The Cap0 is then generated into the Cap1 through 2´-O-Methyltransferase and SAM. Cap1 Capping can also be performed by adding VCE, 2´-O-Methyltransferase, GTP and SAM in a one-step process. Cap 1 structure is more ideal for mammalian systems and possess higher transcription efficiency than Cap 0 structure. The addition of 5-moUTP and poly (A) tail increases the stability and lifetime of the mRNA in vitro and in vivo. Poly (A) tail also plays an important role in enhancing the efficiency of translation initiation.

Description

mRNA Length

726 nucleotides

Concentration

~1 mg/mL

Buffer

1 mM Sodium Citrate, pH 6.4

Storage

-40°C or below

General tips

Please dissolve it on ice and protect from RNase carefully. Avoid repeated freeze/thaw cycles as possible. Don’t vortex. Upon first use, centrifuge the tube softly and aliquot it into several single use portions. Use RNase-free reagents and materials with appropriate RNase-free technique. Don’t add to the media with serum unless mixing with a transfection reagent.

Shipping Condition

ship with dry ice

FAQ

1. How do I choose the right RNA product for my research?

It can be based on your experimental goals:

  • For Tracking Transfection and Translation Efficiency: APExBIO Reporter Gene mRNAs (e.g. EGFP, Firefly Luciferase mRNA) are commonly used to track transfection efficiency and protein expression duration; evaluate gene expression and cell viability; study mRNA localization and bio-distribution via in vivo imaging; optimize transfection conditions and validate LNP delivery system.
  • For Gene Editing, Functional Studies and Gene Therapy Research: APExBIO offers various functional protein mRNAs, involving tumor suppressors (e.g. p53, PTEN), cytokines (e.g. IL-12, IL-10), gene-editing tools (e.g. spCas9, Cre Recombinase), gene replacement protein (e.g. EPO), and antigens (e.g. OVA, SARS-CoV-2 Spike).
  • For Sustained Protein Expression: APExBIO Self-amplifying RNA (saRNA) and Circular RNA (circRNA) are recommended for applications requiring prolonged protein expression. saRNA enables lasting and strong protein expression at lower doses, while circRNA has enhanced structural stability and extended expression duration.
2. What are the key advantages of APExBIO mRNA products?
  • Advanced Capping Technology: Utilizes Cap 1 structure (EZ Cap™ Cap) to achieve enhanced translation efficiency and minimizing activation of the host innate immune response. The capping efficiency can reach 90–99%.
  • Diverse Modification Options: Provides a range of modified nucleotides, such as m1Ψ B8049, 5-moUTP B8061 and Cy5-UTP B8333, which reduce immunogenicity, improve mRNA stability, and maximize protein expression levels.
  • Stringent Quality Control: Each batch undergoes rigorous quality assessment including capping efficiency, purity, integrity, and sterility to ensure batch-to-batch consistency.